Table 1.
Baseline Characteristics
| Patient Characteristics by Treatment | |||
|---|---|---|---|
| CT (N=211) | alloHCT (N=431) | P value | |
| Age | <0.001 | ||
| 60–65 | 66 (31%) | 234 (54%) | |
| 65–70 | 74 (35%) | 157 (36%) | |
| 70–75 | 70 (33%) | 40 (9%) | |
| Missing | 1 | 0 | |
| Gender | 0.07 | ||
| Male | 114 (54%) | 265 (61%) | |
| Female | 97 (46%) | 166 (39%) | |
| Karnofsky score | <0.001 | ||
| <90 | 135 (64%) | 152 (36%) | |
| >=90 | 76 (36%) | 266 (64%) | |
| Missing | 0 | 13 | |
| White Blood Count at diagnosis | 0.01 | ||
| <= 10 | 145 (69%) | 268 (69%) | |
| 10 – 100 | 64 (30%) | 97 (25%) | |
| > 100 | 2 (1%) | 21 (5%) | |
| Missing | 0 | 45 | |
| Extramedullary disease at diagnosis | <0.001 | ||
| No | 161 (87%) | 415 (97%) | |
| Yes | 24 (13%) | 11 (3%) | |
| Missing | 26 | 5 | |
| Cytogenetics scoring | <0.001 | ||
| Normal, Intermediate or Favorable | 105 (50%) | 257 (60%) | |
| Poor | 45 (21%) | 159 (37%) | |
| Missing | 61 (29%) | 15 (3%) | |
| FLT3 mutation | <0.001 | ||
| No | 10 (43%) | 223 (82%) | |
| Yes | 13 (57%) | 48 (18%) | |
| Missing | 188 | 160 | |
| Type of AML | <0.001 | ||
| De-novo | 170 (81%) | 262 (61%) | |
| Secondary | 41 (19%) | 169 (39%) | |
| Consolidation type | <0.001 | ||
| HiDAC | 183 (87%) | 132 (31%) | |
| Other, non-HiDAC | 28 (13%) | 127 (30%) | |
| None | 0 (0%) | 171 (40%) | |
| Missing | 0 | 1 | |
| Other consolidations | |||
| Azacitine plus gemtumzumab | 15 (54%) | ||
| Tipifarnib | 9 (32%) | ||
| Other | 4 (14%) | ||
| Not applicable | 183 | ||
| Number of consolidation cycles | <0.001 | ||
| 0 | 0 (0%) | 171 (43%) | |
| 1 | 56 (27%) | 96 (24%) | |
| 2+ | 155 (73%) | 132 (33%) | |
| Missing | 0 | 32 | |
| Donor Grouping | |||
| HLA-identical sibling | 107 (25%) | ||
| Well-matched unrelated | 178 (41%) | ||
| Partially matched unrelated | 39 (9%) | ||
| Mismatched unrelated | 3 (1%) | ||
| Unrelated matching unknown | 2 (0%) | ||
| Cord blood | 102 (24%) | ||
| Time from Diagnosis to CR1 | 0.24 | ||
| N | 209 | 428 | |
| Mean (SD) | 2.0 (1.8) | 2.1 (2.2) | |
| Median | 1.6 | 1.5 | |
| Q1, Q3 | 1.3,2.2 | 1.0, 2.4 | |
| Range | (0.6–22.5) | (0.2–21.5) | |
| Time from CR1 to consolidation or HCT (months) | <0.001 | ||
| N | 211 | 431 | |
| Mean (SD) | 0.5 (0.5) | 3.5 (2.5) | |
| Median | 0.5 | 3.2 | |
| Q1, Q3 | 0.2, 0.7 | 1.9, 4.7 | |
| Range | (0.0–3.7) | (0.2–20.6) | |
Abbreviations: AlloHCT: allogeneic hematopoietic cell transplantation, CT: chemotherapy consolidation, CR1: first complete remission, HiDac: high dose cytarabine, SD: standard deviation.